

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : MINCHIOTTI, et al. **JC20 Rec'd PCT/PTO 20 SEP 2004**

U.S. Serial No. : Not Yet Known, corresponding to International Application No. PCT/IT04/000133, filed March 19, 2004, which claims priority of Italian Application No. RM2003A000125, filed March 21, 2003 and Italian Application No. RM2003A000370, filed July 29, 2003

Filed : Herewith

For : METHOD FOR PROMOTING THE DIFFERENTIATION OF STAMINAL CELLS

Law Offices of Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, NY 11357

September 20, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Mail Stop Patent Application

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, Applicants would like to direct the Examiner's attention to the following references which are listed below and on Forms PTO/SB/08A and PTO/SB/08B (which are attached hereto as **Exhibit A**), and each individual reference further attached as **Exhibits 1** through **9**.

1. PCT International Search Report for Minchiotti, et al., Int'l Application No. PCT/IT04/000133, Filed March 19, 2004, Dated September 2, 2004 [**Exhibit 1**]
2. PICCOLO, et al., "The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals", Nature, Vol. 397, No. 6721, Pages 707-710 (1999) [**Exhibit 2**]

Applicants : MINCHIOTTI, et al.  
U.S. Serial No.: Not Yet Known  
Filed : Herewith  
Page : 2

**10/550498**

**JC20 Rec'd 20 SEP 2003**

3. PARISI, et al., "Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells", Journal of Cell Biology, Vol. 163, No. 2, Pages 303-314 (2003) **[Exhibit 3]**
4. ADAMSON, et al., "Cripto: A tumor growth factor and more", Journal of Cellular Physiology, Vol. 190, No. 3, Pages 267-278 (2002) **[Exhibit 4]**
5. XU, et al., "Specific arrest of cardioegensis in cultured embryonic stem cells lacking Cripto-1", Developmental Biology, Vol. 196, No. 2, Pages 237-247 (1998) **[Exhibit 5]**
6. BALDASSARRE, et al, "Transfection with a Cripto anti-sense plasmid suppresses endogenous Cripto expression and inhibits transformation in a human embryonal carcinoma cell line", International Journal of Cancer, Vol. 66, No. 4, Pages 538-543 (1996) **[Exhibit 6]**
7. International Publication Number WO 01/68814 A2 for Advanced Research & Technology Institute, Inc., Published September 20, 2001, "Multipotent Cell and Cardiomyocyte Cell Populations, and Routes to and Uses of Same" **[Exhibit 7]**
8. International Publication Number WO 2004/053084 A2 for The Mclean Hospital Corporation, Published June 24, 2004, "Dopaminergic Neurons Differentiated from Embryonic Cells for treating neurodegenerative diseases" **[Exhibit 8]**
9. International Publication Number WO 02/26941 A2 for Van Der Kooy, Derek, Published April 4, 2002, "Primitive neural stem cells and method for differentiation of stem cells to neural cells" **[Exhibit 9]**

Applicants : MINCHIOTTI, et al.  
U.S. Serial No.: Not Yet Known  
Filed : Herewith  
Page : 3

**10/550498**

**JC20 Rec'd PCT/PTO 20 SEP 2009**

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai Kit Chan

Albert Wai-Kit Chan  
Registration No. 36,479  
Attorney for Applicants  
Law Offices of  
Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357  
Tel: (718) 799-1000  
Fax: (718) 357-8615  
E-mail: chank@kitchanlaw.com

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known****Application Number**

Not Yet Known

**Filing Date**

Herewith

**First Named Inventor**

Gabriella MINCHIOTTI

**Art Unit**

Not Yet Known

**Examiner Name**

Not Yet Known

Sheet

1

of

2

**Attorney Docket Number**

1118-PCT-US

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	PCT International Search Report for Minchiotti, et al., Int'l Application No. PCT/IT04/000133, Filed March 19, 2004, Dated September 2, 2004	
	2	PICCOLO, et al., "The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals", Nature, Vol. 397, No. 6721, Pages 707-710 (1999)	
	3	PARISI, et al., "Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells", Journal of Cell Biology, Vol. 163, No. 2, Pages 303-314 (2003)	
	4	ADAMSON, et al., "Cripto: A tumor growth factor and more", Journal of Cellular Physiology, Vol. 190, No. 3, Pages 267-278 (2002)	
	5	XU, et al., "Specific arrest of cardioegensis in cultured embryonic stem cells lacking Cripto-1", Developmental Biology, Vol. 196, No. 2, Pages 237-247 (1998)	
	6	BALDASSARRE, et al., "Transfection with a Cripto anti-sense plasmid suppresses endogenous Cripto expression and inhibits transformation in a human embryonal carcinoma cell line", International Journal of Cancer, Vol. 66, No. 4, Pages 538-543 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JC20 Rec'd PCT/PTO 20 SEP 2001  
 PTO/SB/ Approved for use through 04/30/2003. OMB

PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

***(Use as many sheets as necessary)***

Sheet	2	of	2
-------	---	----	---

**Complete if Known**

Application Number Not Yet Known 498

Filing Date Herewith

First Named Inventor	Gabriella MINCHIOTTI
----------------------	----------------------

Art Unit	Not Yet Known
----------	---------------

Examiner Name	Not Yet Known
---------------	---------------

Attorney Docket Number	1118-PCT-US
------------------------	-------------

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	7	WO 01/68814 A2	09-20-2001	Advanced Research & Technology Institute, Inc.		
	8	WO 2004/053084 A2	06-24-2004	The Mclean Hospital Corporation		
	9	WO 02/26941 A2	04-04-2002	Van Der Kooy, Derek		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*